ELSA Exposome Enhancement Relevant to Alzheimer's Disease and AD-related Dementias

ELSA 暴露体增强与阿尔茨海默病和 AD 相关痴呆症相关

• 批准号: 10661220
• 负责人: Andrew Steptoe
• 金额: $ 173.28万
• 依托单位: UNIVERSITY COLLEGE LONDON
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-11 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10661220
• 关键词: Address; Adult; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Biological; Biological Markers; Birth; Blood; Blood specimen; Chemical Exposure; Child Development; Childhood; Cognition; Cognitive; Cohort Analysis; Data; Dementia; Development; Dimensions; Drug Targeting; Economic Factors; Environmental Exposure; Family; Funding; Future; Health; Health behavior; Impaired cognition; Individual; Life Cycle Stages; Life Experience; Longitudinal Studies; Measures; Modeling; Parents; Participant; Pathway interactions; Population Study; Proteins; Proteomics; Protocols documentation; Role; Sampling; Time; Trauma; Work; childhood adversity; cognitive testing; cohort; dementia risk; early life adversity; ethnic minority; experience; genome-wide; innovation; life history; member; migration; mild cognitive impairment; novel; prospective; psychosocial; racial and ethnic; recruit; residence; sociodemographic factors; tool

The English Longitudinal Study of Ageing (ELSA) is an important platform for population-based studies of Alzheimer’s Disease and Alzheimer’s Disease Related Dementias for several reasons. First, it has been in progress since 2002 with repeated measures of health, cognition, biomarkers, sociodemographic and economic factors, allowing for the long-term determinants of dementia to be analyzed. Second, the Harmonized Cognitive Assessment Protocol (HCAP) was administered in ELSA in 2018, and a second HCAP is planned for 2023, providing comprehensive data related to dementia and mild cognitive impairment that can be extrapolated to the complete cohort. Third, ELSA is closely modelled on HRS, facilitating detailed comparisons and replication. This application is for funds to enhance exposure measures relevant to AD/ADRD in two important dimensions identified in the NOSI that are central to the parent R01: biological innovation and enrichment of psychosocial measures. First, we plan to carry out proteomic profiling of the ELSA cohort using bloods collected in 2004 and 2008. The relationship between protein levels and cognitive decline and the development of dementia will, in conjunction with existing genome-wide assessments and existing biomarkers, provide a powerful tool for identifying novel pathways that could be of value as future drug targets. We will use the Olink proteomic platform that is being applied in a subsample of the HRS, as well as in the National Child Development Study (NCDS) 1958 birth cohort in the UK. The use of common tools will enable cross-cohort analysis in the future, and will support the replicability of findings. The second focus of this application is on the enhancement of the life history data in ELSA. The life history module was administered in 2007, and since then the sample has been refreshed several times. We therefore do not know about the experiences of around 44% of the current members of ELSA before they joined the study. We plan to offer a full life history assessment to these individuals, while adding some more detailed questions for those who previously completed the module. We will collect information about places of residence, work and earnings, partners and family, migration, health, and health behaviors through the life course, together with childhood living conditions and childhood adversity. Administration of the module to the new racial/ethnic minority sample being recruited in wave 10 (2021-2022) of ELSA will result in the first large-scale quantitative assessment of the life histories of these groups in the UK. The data will allow future analyses of issues such as cognitive stimulation during work, adult trauma, and early adversity in relation to AD/ADRD risk, while providing the platform for linkage with life course physical and chemical exposures. We will also address the issue of the validity of retrospective measures of life history by comparisons with the prospective data collected in the NCDS 1958 birth cohort, to obtain an accurate picture of the robustness of retrospective accounts of earlier life experiences.

英语衰老纵向研究（ELSA）是基于人群的研究 阿尔茨海默氏病和阿尔茨海默氏病与痴呆有关的痴呆症的原因有多种。 自2002年以来的进步，重复衡量健康，认知，生物标志物，社会人口统计学和 经济因素，可以分析痴呆症的长期决定因素。 2018年在ELSA中管理了统一认知评估方案（HCAP），第二个 HCAP计划于2023年，提供与痴呆症和轻度认知的全面数据 可以推断到完整的队列，第三，Elsa是在HRS上进行的，促进 详细的比较和复制。 在NOSI中确定的两个重要的代数中的AD/ADRD是父母R01的核心： 生物学创新和精神措施，我们计划进行蛋白质组学 使用2004年和2008年收集的血液对ELSA队列的分析。蛋白质之间的关系 水平和认知能力下降以及痴呆症的发展将与现有的全基因组结合 评估和现有的生物标志物提供了一种强大的工具，这些工具是可以使用新颖的途径 作为未来的药物靶标的价值。 HRS以及国家儿童发展研究（NCDS）1958年的出生队列 将来可以通过启用跨局部分析的常见工具，并将支持调查结果的可复制性。 艾尔莎（Elsa）生活的第二个重点。 历史模块是在2007年管理的，因为样品已经刷新了几次 因此，在他们之前不了解大约44％的Elsa成员的经历 加入了研究。 对于那些完成该模块的人的详细问题。 通过你的居住，工作和收入，合作伙伴和家庭，移民，健康和健康行为 生活课程，以及童年的生活条件和童年逆境。 ELSA的第10波（2021-2022）中招募的新种族/族裔少数民族样本将持续第一次 对这些群体的生活历史的大规模定量评估。 分析工作期间认知刺激和关系的地球逆境等ISS的分析 AD/ADRD风险，同时提供与生命课程物理和化学曝光的平台 还将通过与之进行比较来解决生活历史回顾性衡量标准的ISSE 在1958年出生队列中收集的前瞻性数据，以获取准确的鲁棒性图片 回顾性的较早生活经验。